InsidersTradesSigma
Total declarations
Companies
▲ Purchases (7 ops.)
▼ Sales (3 ops.)
Insider track record
ExecutiveDisclosed buys
7
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Schmid John P., Directeur. Director active across 7 companies, notably Xeris Pharmaceuticals INC. In total, 26 reports have been recorded. Split: 7 buys · 3 sells. Total volume traded: €1.2m. History available since 8 June 2022. The latest transaction was disclosed on 10 August 2026 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Schmid John P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations26 total
6,000 shares@ US$16.00100.0% of flowCommon StockSEC:0001478916-26-000015:0
Canonical exit: 8 Nov 2026 (T+90)
6,030 sharesCommon StockSEC:0001478916-26-000011:0
12,596 shares@ US$55.708734.5% of flowCommon StockSEC:0001478916-26-000004:0
7,527 shares@ US$56.700221.0% of flowCommon StockSEC:0001478916-26-000004:1
522 shares@ US$57.39891.5% of flowCommon StockSEC:0001478916-26-000004:2
11,068 shares@ US$51.0062.9% of flowCommon StockSEC:0001478916-25-000004:0
30,000 sharesCommon StockSEC:0001213900-25-074364:0
6,030 shares0Common StockSEC:0001415889-25-017587:0
11,068 shares@ US$18.182224.4% of flowCommon StockSEC:0001415889-25-009100:0
21,692 shares@ US$4.5512.6% of flowCommon StockSEC:0001415889-25-001501:0
58,950 sharesCommon StockSEC:0001415889-25-001088:0
4,515 shares@ US$2.247420.2% of flowCommon StockSEC:0001867096-24-000176:0
Canonical exit: 10 Nov 2024 (T+90)
4,285 shares@ US$2.36520.2% of flowCommon StockSEC:0001867096-24-000173:0
Canonical exit: 7 Nov 2024 (T+90)
3,900 shares0Common StockSEC:0001415889-24-017510:0
19,650 shares0Common StockSEC:0000950170-24-074875:0
50,000 shares0Common StockSEC:0001867096-24-000110:0
5,400 shares@ US$1.9120.8% of flowCommon StockSEC:0001867096-24-000067:0
Canonical exit: 8 Aug 2024 (T+90)
9,156 shares@ US$3.6187100.0% of flowCommon StockSEC:0001415889-24-009063:0
Canonical exit: 20 Jun 2024 (T+90)
4,500 shares@ US$2.1619.3% of flowCommon StockSEC:0001867096-24-000034:0
Canonical exit: 12 Jun 2024 (T+90)
6,500 shares@ US$1.5119.6% of flowCommon StockSEC:0001867096-23-000147:0
Canonical exit: 14 Feb 2024 (T+90)
19,650 shares0Common StockSEC:0000950170-23-028607:0
42,500 shares0Common StockSEC:0001867096-23-000093:0
19,650 shares0Common StockSEC:0001209191-22-037667:0
15,000 shares0Common StockSEC:0001867096-22-000091:0
5,659 sharesCommon StockSEC:0000899243-21-039257:0
25 of 26 declarations
About Schmid John P.
Schmid John P. is Director and appears in 25 filings. In the 25 sampled filings, buys total EUR 76542 and sells total EUR 1010865, with activity spanning from 2021-10-05 to 2026-06-17. The companies listed are Anaptysbio, INC, Xeris Biopharma Holdings, Inc., Poseida Therapeutics, Inc., BridgeBio Oncology Therapeutics, Inc., Design Therapeutics, Inc., and Xeris Pharmaceuticals INC.
